Engineering Medicines To Improve Patient Care


Treatments Targeting Patients’ Needs

“Viridian is developing creative solutions to ease patient burdens – burdens from their disease but also the burdens patients often bear in receiving clinically efficacious interventions. We aspire to develop medications that improve patients’ lives safely, tolerably, and conveniently.”
– Barrett Katz, MD, MBA, Chief Medical Officer

About TED

TED is a debilitating auto-immune disease that causes inflammation and fibrosis (scarring) of the tissues surrounding and behind the eye. This leads to proptosis, (bulging of the eyes) redness and swelling, diplopia (double vision), pain, and potential blindness. As the disease progresses patients have difficulty reading, driving and performing routine activities of daily living, leading to a high physical and mental burden that significantly impacts their quality of life. Historically, TED patients have had poor treatment options limited to orbital surgeries, radiation and long term corticosteroids. Current treatments options remain limited and burdensome.

We aim to develop an easily administered therapy targeting a major culprit in the TED disease process – the insulin-like growth factor-1 receptor (IGF-1R). Our goal is to develop the most complete, safe, and convenient option.

Clinical Trials

Viridian is developing treatments for Thyroid Eye Disease (TED), a debilitating auto-immune disease. Randomized, placebo controlled clinical trials are the mechanism dictated by the Food and Drug Administration that allows us to evaluate innovative new treatments to demonstrate efficacy, safety and tolerability of our pipeline products. We have initiated our first clinical trial in TED, seeking to enroll patients diagnosed with TED in the last 12 months.

For further inquiries or to request more information and updated trial information, email us at